Potential Drug Dosing Variability in Women. Jim Beaulieu, PharmD Senior Clinical Pharmacist Specialist Rhode Island Hospital and The Miriam Hospital

Similar documents
Geriatric Pharmacology. Kwi Bulow, M.D. Clinical Professor of Medicine Director, Academic Geriatric Resource Center

Diabetes and the Elderly: Medication Considerations When Determining Benefits and Risks

Basic Biopharmaceutics, Pharmacokinetics, and Pharmacodynamics

Biology of Aging. Faculty Disclosure. Learning Objectives. I have no relevant financial disclosures relative to the content of this presentation.

Pharmacology in the Elderly

Pharmacotherapy Issues in the Pediatric Population

Aging Changes That Impact Medication Management

Variation in drug responses & Drug-Drug Interactions

eview Top 10 Prescribed Drugs: Important Interactions Karen A. Jensen, MSc, BSP yright t for Sale or Commercial Distribution

COMMON DRUG RELATED PROBLEMS SEEN IN PACE AND MECHANISMS TO MITIGATE RISK

Cytochrome P450 Drug Interaction Table Flockhart Table

Prevention of Medication-Related Falls Through Appropriate Medication Use. Clay Sprouse, MEd., CPhT Piedmont Technical College

Michael Kozart, MD, PhD

Geriatric Pharmacology

Can PK and Modelling Help?

Polypharmacy and Common Drug Interactions in Geriatric Patients

Prescribing Drugs to the Elderly

Pharmacokinetics PCTH 325. Dr. Shabbits September 12, C t = C 0 e -kt. Learning Objectives

2/25/2015 PHARMACODYNAMICS OF AGING: NARROWING OF THE THERAPEUTIC INDEX IN THE FACE OF THERAPEUTIC OPPORTUNITY OVERALL PRESCRIBING

2/26/2015 PHARMACODYNAMICS OF AGING: NARROWING OF THE THERAPEUTIC INDEX IN THE FACE OF THERAPEUTIC OPPORTUNITY

LACIPIL QUALITATIVE AND QUANTITATIVE COMPOSITION

Younger adults with a family history of premature artherosclerotic disease should have their cardiovascular risk factors measured.

Perfect Endings. Home Alone. Senior Estimate. Staying Alive. Medication Madness

Polypharmacy. in the Elderly. Lesley Charles, MBChB, CCFP

Neither activated charcoal nor whole bowel irrigation (WBI) is indicated in the routine management of acute or chronic lithium toxicity.

Spironolactone has not been demonstrated to elevate serum uric acid, to precipitate gout or to alter carbohydrate metabolism.

START, STOPP, Beers Oh My! Navigating the World of Geriatric Pharmacy

Rebecca Rottman-Sagebiel, Pharm.D., BCPS Sharon Jung Tschirhart, Pharm.D., BCPS Geriatric Clinical Pharmacy Specialists STVHCS, Audie L.

Identifying and Managing Chronic Kidney Disease: A Practical Approach

Pharmaceutical Care for Geriatrics

DYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D

OBJECTIVES. Key issues in geriatric pharmacology. Effects of age on pharmacokinetics and pharmacodynamics

Contemporary Nutrition 6 th. th ed. Chapter 9 Minerals

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

Low Efficacy Diuretics. Potassium sparing diuretics. Carbonic anhydrase inhibitors. Osmotic diuretics. Miscellaneous

A Case of Severe Hypomagnesemia with Long-term Use of a Proton Pump Inhibitor

Chapter 23. Media Directory. Cardiovascular Disease (CVD) Hypertension: Classified into Three Categories

Can take vitamin d verapamil

Aging and Geriatric Assessment March 31, 2008 Sharon Leigh, Pharm D. BCPS Providence ElderPlace

Instrumental determination of electrolytes in urine. Amal Alamri

Brand and Generic Drugs. Educational Objectives. Absorption

DIAGNOSIS AND MANAGEMENT OF DIURETIC RESISTANCE. Jules B. Puschett, M.D.

Drug Therapy Following Bariatric Surgery

Medication Use in Older Adults

keyword: diuretics Drug monitoring Monitoring diuretics in primary care 2 March 2009 best tests

Chapter-V Drug use in renal and hepatic disorders. BY Prof. C.Ramasamy, Head, Dept of Pharmacy Practice SRM College of Pharmacy, SRM University

COMMON DRUG INTERACTIONS: A PRACTICAL REVIEW FOR PHARMACY TECHNICIANS

WEEK. MPharm Programme. Acute Kidney Injury. Alan M. Green MPHM13: Acute Kidney Injury. Slide 1 of 47

POLYPHARMACY IN OLDER ADULTS AND BEERS CRITERIA UPDATE

Swiss Summary of the Risk Management Plan (RMP) for Parsabiv (Etelcalcetide)

Long-Term Care Updates

New Osteoporosis Guidelines: What you and your health provider need to know QUESTION & ANSWER

Hearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds

Onfi (clobazam) Labeled Uses: Clobazam is used as adjuvant treatment of seizures from Lennox-Gastaut Syndrome. 1,2

PHARMACOTHERAPY IN THE OLDER PERSON NAMIRAH JAMSHED M.B;B.S ASSOCIATE PROFESSOR UTSW MEDICAL CENTER DALLAS

Current Approaches and Applications of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters

Active ingredients: Pantoprazole sodium 45.1 mg equivalent to 40 mg Pantoprazole base

Pharmacokinetics of strong opioids. Susan Addie Specialist palliative care pharmacist

Breast Pathway Group EC x 4 Paclitaxel x 4 (3-weekly): Epirubicin & Cyclophosphamide x 4 followed by Paclitaxel x 4 (3-weekly) in Early Breast Cancer

Composition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:

RISK FACTORS AND DRUG TO STATIN-INDUCED MYOPATHY

Chapter 27: WATER, ELECTROLYTES, AND ACID-BASE BALANCE

Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program November 4, 2010 National

Each tablet contains:

Prescribing and Pharmacokinetic Considerations in the Elderly

Medicines Q&As Q&A What should be considered when prescribing medicines for patients who have undergone bariatric surgery?

Why Talk about Alcohol? Lecture 14: Alcohol. Consuming Alcohol in Moderation

Dysnatremias: All About the Salt? Internal Medicine Resident Lecture 1/12/16 Steve Schinker, MD

PHARMACOKINETICS SMALL GROUP I:

Executive Report was an active year for the Regional Center for Poison Control and Prevention Serving Massachusetts and Rhode Island.

Pharmacokinetics in the critically ill. Intensive Care Training Program Radboud University Medical Centre Nijmegen

DEPARTMENT OF PHARMACOLOGY AND THERAPEUTIC UNIVERSITAS SUMATERA UTARA

PHARMACEUTICAL INFORMATION AZILSARTAN

Hypertension Update. Sarah J. Payne, MS, PharmD, BCPS Assistant Professor, Department of Pharmacotherapy UNT System College of Pharmacy

Top 200 Section 4. Cardiovascular Drugs

MEDICATION GUIDE Abacavir, Lamivudine and Zidovudine Tablets (a-bak-a-vir, la-miv-ue-deen, zye-doe-vue-deen)

There s A Pill For That (But should my patient be on it?) A Review of Tools for the Evaluation of Optimal Prescribing in Geriatric Patients

7/7/ CHD/MI LVH and LV dysfunction Dysrrhythmias Stroke PVD Renal insufficiency and failure Retinopathy. Normal <120 Prehypertension

DRUGS THAT ACT IN THE CNS

UNIVERSITY OF PNG SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES Discipline of Biochemistry and Molecular Biology

Sometimes dogs need something a little extra!

Antibiotic Utilization in SNF/LTC Role of Consultant Pharmacist

ANTIANXIETY DRUGS: BENZODIAZEPINES

Effects of Liver Disease on Pharmacokinetics

Summary of the risk management plan (RMP) for Zykadia (ceritinib)

Adams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS

12/19/16. Disclosures

Principles of Medication Use in Older Adults ANNE L. HUME, PHARMD PROFESSOR OF PHARMACY UNIVERSITY OF RHODE ISLAND

Patient Getting Smart About Medications Education If the kidneys are not working well, less waste is removed, including

Medical Translation: Welcome to our webinar

History of hypersensitivity to AMPYRA or 4-aminopyridine (4)

How to Teach About Drugs and Aging

SUMMARY OF PRODUCT CHARACTERISTICS

Towards a Greater Understanding of Cardiac Medications Foundational Cardiac Concepts That Must Be Understood:

Psychopharmacology in the Emergency Room. Michael D. Jibson, M.D., Ph.D. Professor of Psychiatry University of Michigan

Amlodipine plus Lisinopril Tablets AMLOPRES-L

Heart Disease and Prevention PRESENTED BY: DOTTIE CRAIG NP- C, JANE ARCHER NP-C, KATHY DAPPER RN, NICCI FRAVEL RN

Drug Interactions Year 2 Clinical Pharmacology

DALFAMPRIDINE Extended-release tablets, for oral use. Initial U.S. Approval: 2010

Transcription:

Potential Drug Dosing Variability in Women Jim Beaulieu, PharmD Senior Clinical Pharmacist Specialist Rhode Island Hospital and The Miriam Hospital

2 Objectives Understand the pharmacokinetic variability found in the elderly, female patient. Discuss specific changes found in each pharmacokinetic phase (absorption, distribution, metabolism, and elimination)

Dose Response Influencing Factors (response): Dose (bioavailability) Age Weight (Obesity) Sensitivity Renal/Hepatic Function Genetics Responder/Nonresponder Race Gender Interactions with other meds/herbals Smoking and alcohol use Diet Pharmacokinetic Principals (dictates amount available) Absorption Distribution Metabolism Elimination

Absorption (Bioavailability) Are gender differences clinically significant? Gastric ph higher in women Some medications require acid to be absorbed Loss of gastric acid production continues as you age Bowel transit time are usually longer Inactive ingredients may affect absorption Polyethylene glycol enhances bioavailability of ranitidine (Zantac) in men by up to 63% Decreased in women up to 24%

Distribution Women have a higher percentage of adipose mass vs. men (25% vs 16%) Difference less as we age Accumulation of lipophilic drugs in adipose tissue such as benzodiazepines (e.g., Valium, amitriptyline) Prolonged half-life Tissue accumulation Exposure-related adverse effects

Distribution Women have a lower plasma volume than men Plasma volume continues to decline as you age May affect drugs that are water soluble Potential for increased blood concentrations and increased activity: ex: ethanol, acetaminophen and digoxin Lower organ blood-flow rate Continues to decline as you age Decreased cardiac output

Metabolism CYP Enzyme Gender differences in activity Examples CYP1A2 Women < men Clozapine (Clozaril) Olanzapine (Zyprexa) CYP2D6 Women < men Dextromethorphan Metoprolol (Lopressor) CYP3A Women > men Midazolam (Versed), Nifedipine (Procardia), Triazolam (Halcion) CYP2C9 Women = men Fluvastatin CYP2C19 Women = men Mephenytoin < (decreased metabolism, greater exposure) > (greater metabolism, less exposure) = (similar metabolism and exposure)

Metabolism Lower rate of blood flow to the liver Decreased delivery of medications to the liver Women take more prescription medications and OTC/herbal products than men Potential for greater exposure due to a higher frequency of drug-drug-interactions

9 Renal Excretion Renal clearance generally higher in men Body weight differences GFR directly proportional to lean body weight As we age: Beginning at age 40, ~10% reduction in GFR & renal plasma flow per decade By age 70 a person may have a decrease of up to 70 %, even in the absence of kidney disease decrease in muscle mass due to normal aging decrease production of creatinine.

10 Calculating CrCl 1. Measure serum creatinine Plasma concentration 24 hour urine collection 2. Patient s age (years) 3. Patient s weight (kg) CrL = (140 age)* wt 72 * SrCr Multiply by 0.8 for women

11 Normal Results of the Aging Process Alterations in body composition a increase in body fat b decrease in fat free mass c decrease in total body water d decrease in serum albumin concentration e decrease in visceral blood flow f increase in bone loss

Gender Differences - Pharmcodynamics Lengthening of the QT interval Women at greater risk to develop torsade de pointes from drugs that prolong cardiac repolarization Effect of sex hormones on activity of potassium channels Progesterone may have a protective effect Greatest QTc response found during the menstrual and ovulation phases of the cycle. Monitor and reduce risk Serum electrolyte levels (low potassium and or magnesium) Ischemia Concurrent use of other drugs that prolong the QTc interval

13 Medication Examples Statin induced myopathy Women Frail individuals Low body mass index Hypothyroidism Poly-pharmacy Alcohol abuse Vitamin D deficiency Use CYP enzymes for vitamin D hydroxylation Increase exposure to statin

14 Medication Examples 2012 study revealed a 35% higher risk of hip fracture in women regularly using PPIs for at lest 2 years Decreased absorption of calcium Association stronger in current and former smokers

15 Medication Examples Selective Serotonin Reuptake Inhibitors Beers drugs due risk of falls and hyponatremia due to SIADH Risk factors Older age Female sex Low body weight Use of diuretics Baseline hyponatremia Monitor sodium levels Especially if above risk factors

16 Medication Examples Amlodipine (Norvasc) Possible increase risk of adverse events in women on higher doses Bioavailability higher in women More often in women of lower body weight Adverse Event Male (%) Female (%) Male (%) Female (%) (N=1218) (N=512) (N=914) N=336) Edema 5.6 14.6 1.4 5.1 Flushing 1.5 4.5 0.3 0.9 Palpitations 1.4 3.3 0.9 0.9 Somnolence 1.3 1.6 0.8 0.3

Zolpidem (Ambien) Beers medication Medication Examples Metabolized in the liver Increased exposure in patients with liver impairment FDA product labeling change: no more than 5 mg in the elderly Rate of absorption higher in women vs men 45% higher for immediate release tablet 50-75% higher for sustained release tablet January 2013 FDA Safety Alert Initial dose immediate-release: 5 mg for women and either 5 mg or 10 mg for men. Initial dose of zolpidem extended-release is 6.25 mg for women and either 6.25 or 12.5 mg for men. Lower doses not effective, increase to 10 mg for immediate-release products and 12.5 mg for extended-release Increase risk of next-day impairment of driving and other activities that require full alertness.

18 Overall Goal: Avoid Adverse Events Beers List Standard for inappropriate medications At least 23% of older adults take > 1 medications on Beers List Linked to poor health outcomes Higher risk of hospitalization or ED evaluation http://onlinelibrary.wiley.com/doi/10.1111/jgs.13702/ pdf There s an app for it!

What can we do: Putting it all together 1. Accurate and comprehensive medication assessment 2. Use of strategies to optimize medication use while minimizing risk of adverse drug events 3. Collaboration with all members of interdisciplinary team 4. Staff and family education 19

Questions 20